The Phase 1 dose escalation study will evaluate GTB-3650 in up to approximately 14 patients (seven cohorts) with relapsed or refractory (r/r) CD33 expressing hematologic malignancies, including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback